



NUTRITION UNIT

# SCIENTIFIC PANEL ON NUTRITION, NOVEL FOODS AND FOOD ALLERGENS

## MINUTES OF THE 106<sup>TH</sup> PLENARY MEETING

**Held on 22-23 September 2020 via web conference  
(Agreed on 29 September 2020)**

### Participants

■ Panel Members:

Jacqueline Castenmiller, Stefaan de Henauw, Karen Ildico Hirsch-Ernst<sup>1</sup>, John Kearney, Helle Katrine Knutsen, Alexandre Maciuk<sup>2</sup>, Inge Mangelsdorf, Harry J. McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Dominique Turck (Chair) and Marco Vinceti.

■ Hearing Experts:

Not Applicable

■ European Commission:

Yvette Azzopardi,<sup>2</sup> Stella D'Amore and Fruzsina Nyemecz<sup>2</sup>

■ EFSA:

NUTRI Unit: Valeriu Curtui, Janusz Ciok, Agnès Desesmaisons-Lecarré, Céline Dumas, Lucia Fabiani, Leng Heng, Ariane Titz and Silvia Valtueña Martínez

AMU Unit: Laura Ciccolallo and Laura Martino<sup>2</sup>

DATA Unit: Davide Arcella and Zsuzsanna Horvath<sup>1</sup>

■ Others:

Not Applicable

<sup>1</sup> Attended only 22 Sep 2020

<sup>2</sup> Attended only 23 Sep 2020



## 1. Welcome and apologies for absence

The Chair welcomed the participants. No apologies were received.

## 2. Adoption of agenda

The agenda was adopted without changes.

## 3. Declarations of Interest of Scientific Panel members

In accordance with EFSA's Policy on Independence<sup>3</sup> and the Decision of the Executive Director on Competing Interest Management<sup>4</sup>, EFSA screened the Annual Declarations of Interest filled out by the Panel members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process, and no interests were declared orally by the members at the beginning of this meeting.

## 4. The minutes of the 105<sup>th</sup> Plenary meeting held on 31 August 2020

The [minutes](#) of the 105<sup>th</sup> Plenary meeting held on 31 August 2020 were agreed by written procedure on 04 September 2020.

## 5. Scientific outputs submitted for discussion and/or possible adoption

### 5.1 **Draft opinion on Anxiofit-1 and reduction of subthreshold and mild anxiety - Applicant: Anxiofit Limited. (0493\_HU - Art. 14 Claim, Reg. (EC) No 1924/2006, EFSA-Q-2020-00032)**

The draft opinion was presented. The Panel reviewed and discussed the sections regarding the characterisation of the food/constituent, relevance of the claimed effect to human health, and the scientific substantiation of the claimed effect taking into consideration the data submitted in the present application including the applicant's reply to EFSA's stop-the-clock letter. The opinion was adopted by the Panel on 23 September subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6264>

### 5.2 **Draft opinion on the safety and suitability of a formula based on protein hydrolysates – Applicant: Nestlé Nutrition UK & I (EFSA-Q-2019-00547)**

The draft opinion was presented. The Panel reviewed and discussed the sections regarding the characterisation of the protein hydrolysate, the characterisation of the formula manufactured from this hydrolysate and used in the clinical studies provided, and the human intervention studies submitted to support the nutritional safety and suitability of the protein hydrolysate. The Panel considered that further information with respect to human intervention studies was needed. Therefore, a request for additional information and clarification will be sent to the applicant and a stop-the-clock procedure will be applied.

<sup>3</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/policy\\_independence.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf)

<sup>4</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/competing\\_interest\\_management\\_17.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf)



## 6. New mandates

The Panel took note that a new mandate was received (Art 29) on the conversion factor of calcium-L-methylfolate and (6S)-5-methyltetrahydrofolic acid, glucosamine salt into dietary folate equivalent, and that there was a need for setting up a new working group. Kristina Pentieva has been appointed as the chair of the WG. The full composition of the WG, once established, will be published on the EFSA website. For information on the mandate and the status, please refer to [EFSA Register of Questions](#).

## 7. Feedback from the Scientific Committee/Scientific Panels, EFSA, the European Commission

Postponed.

## 8. Other scientific topics for information and/or discussion

### 8.1 Draft Scientific opinion on the Tolerable Upper Intake Level of dietary sugars (EFSA-Q-2016-00414)

The Panel took note of the methodology used to establish the EFSA composition databases for total, free and added sugars. The results of the intake assessment, as well as the responses to the questionnaire sent to Member States, were presented and discussed.

The Panel was presented with the principles developed for evidence integration and uncertainty analysis in relation to metabolic disease endpoints. This point will be discussed again at the next Plenary meeting.

## 9. Any Other Business

- With reference to the Tolerable Upper Intake Levels for vitamins and minerals, the Panel discussed scientific evidence that has emerged since the last opinions of the Scientific Committee on Food/NDA Panel were published between 2000 and 2005 and compiled in an [EFSA report](#) that was published in 2006.
- The Panel took note of EFSA recommendations to facilitate the operation of Working Groups (WG) and Panels meetings. The WG chair may be invited to participate in a given WG meeting in the role of chair or as member based on the decision whether the agenda topics are sensitive and/or complex.
- The next plenary meeting of the NDA Panel is scheduled on 22 October 2020 via web conference.